Evidence map›Paper›PMID 38067312›Full record

ArticleCancers2023

Homologous Recombination Repair Gene Alterations Are Associated with Tumor Mutational Burden and Survival of Immunotherapy.

Mamoru Ito, Makoto Kubo, Hitomi Kawaji, Yoshiki Otsubo, Kanako Kurata, Hikaru Abutani, Mikita Suyama, Yoshinao Oda, Tomoharu Yoshizumi, Masafumi Nakamura and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mamoru ItoDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan.
Makoto KuboDepartment of Breast Surgical Oncology, Kyushu University Hospital, Fukuoka 812-8582, Japan.ORCID 0000-0001-6000-8731
Hitomi KawajiDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.ORCID 0000-0002-8259-8063
Yoshiki OtsuboDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Kanako KurataDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Hikaru AbutaniFoundation Medicine Unit, Foundation Medicine Business Department, Chugai Pharmaceutical Co., Ltd., Tokyo 103-8324, Japan.ORCID 0000-0002-8792-9677
Mikita SuyamaDivision of Bioinformatics, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan.ORCID 0000-0001-9526-3193
Yoshinao OdaDepartment of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Tomoharu YoshizumiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.ORCID 0000-0002-4497-1816
Masafumi NakamuraDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Eishi BabaDepartment of Oncology and Social Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

Funding

the Japan Society for the Promotion of Science KAKENHI 18J20301 and 18K08577
6 · The paper itself

Abstract

backgroundComprehensive genomic profiling (CGP) has become generally accepted practice in cancer care since CGP has become reimbursed by national healthcare insurance in Japan in 2019. However, its usefulness for cancer patients is insufficient for several reasons.

methodsIn an observational clinical study of FoundationOne

resultsThe primary tumor sites of the 220 cases were breast (115), colon (29), stomach (19), and pancreas (20). The present dataset suggested that homologous recombination repair (HRR) gene alterations were positively associated with tumor mutational burden-high (TMB-high) (

conclusionsHRR gene alterations can be a potential biomarker predicting TMB-high and a good response to immunotherapy. For successful sequencing, samples with lower percentages of tumor cell nuclei and previous neoadjuvant chemotherapy should be avoided.

Indexed as

ARID1Acomprehensive genomic profilinghomologous recombination repair genetumor mutational burden

Identifiers

PMID38067312
PMCPMC10705153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.